salwa
essaad
nicola
tremblay
martin
baril
daniel
lamarr
interferon
ifn
long
use
immunomodulatori
therapi
larg
array
acut
chronic
viral
infect
howev
ifn
therapi
plagu
sever
side
effect
discoveri
pathogen
recognit
receptor
prr
rejuven
interest
immunomodulatori
therapi
success
obtain
tolllik
receptor
tlr
agonist
activ
immun
cell
adjuv
prophylact
vaccin
differ
virus
pave
way
target
immunomodulatori
therapi
better
character
pathogeninduc
immun
disord
newli
discov
regul
innat
immun
potenti
specif
withdraw
prevail
subvers
mechan
transform
antivir
treatment
introduc
panvir
therapeut
less
advers
effect
ifn
therapi
innat
immun
system
first
line
defens
organ
possess
adapt
immun
system
reli
presenc
specif
receptor
abl
recogn
recur
pattern
molecul
associ
pathogen
host
cell
allow
discrimin
self
nonself
receptor
name
pattern
recognit
receptor
prr
recogn
pathogenassoci
molecular
pattern
pamp
induc
express
cytokin
chemokin
restrict
dissemin
elimin
pathogen
instruct
pathogenspecif
adapt
immun
respons
recent
year
tremend
advanc
character
prr
famili
nucleic
acid
sens
downstream
signal
pathway
effector
respons
reveal
essenti
role
novel
protein
dynam
protein
interact
network
trigger
immun
respons
intracellular
pathogen
virus
near
futur
target
specif
regul
prrmediat
innat
respons
withdraw
viral
subvers
mechan
access
novel
surrog
measur
effector
marker
hold
promis
new
panvir
therapeut
minim
advers
effect
associ
type
ifn
therapi
review
briefli
summar
strategi
challeng
present
futur
target
immunomodulatori
therapi
accord
increas
knowledg
regul
innat
immun
virusinduc
immun
host
dysfunct
signal
ppr
includ
major
famili
tolllik
receptor
tlr
retino
acidinduc
gene
rigi
like
receptor
rlr
nucleotidebind
oligomer
domain
nod
like
receptor
nlr
pathogen
sens
take
place
nucleat
cell
gener
cellintrins
innat
immun
profession
antigen
present
cell
apc
promot
specif
adapt
immun
respons
tlr
sens
pamp
extracellular
space
endosom
rlr
nlr
function
pathogen
sensor
intracellular
compart
interestingli
known
tlr
abil
recogn
viral
molecul
viral
dsrna
viral
ssrna
viral
unmethyl
cpg
dna
three
cytosol
sensor
viral
rna
character
thu
far
rigi
sens
triphosph
structur
bluntend
base
pare
sens
long
dsrna
cardless
regul
counterpart
follow
activ
card
domain
rigi
interact
card
domain
signal
adaptor
mav
mitochondri
antivir
signal
protein
tlr
rlr
viral
sens
pathway
converg
activ
ifn
regulatori
factor
type
ifn
ab
antivir
respons
nfkbmediat
inflammatori
pathway
figur
recent
studi
aim
better
defin
innat
immun
respons
identifi
sever
novel
signal
regulatori
molecul
global
proteom
analysi
reveal
signal
modul
high
interconnect
adaptor
protein
regul
signalosom
assembl
upon
antivir
respons
type
ifn
product
cytokin
type
ifn
increas
express
mhc
class
ii
antigen
apc
cytokin
produc
site
infect
play
key
role
activ
differenti
dendrit
cell
dc
macrophag
neutrophil
nk
cell
major
player
innat
immun
respons
figur
matur
dc
detect
viru
deriv
antigen
migrat
lymph
node
present
antigen
cell
b
cell
induc
activ
thu
modul
prrmediat
antivir
respons
import
rippl
effect
qualit
quantit
aspect
specif
adapt
immun
respons
maxim
therapeut
potenti
immunomodulatori
drug
neg
regul
innat
immun
respons
patholog
consequ
antivir
innat
respons
must
tightli
regul
order
prevent
uncontrol
product
cytokin
might
deleteri
effect
host
type
ifn
signatur
induc
prr
activ
observ
divers
autoimmun
disord
includ
diabet
believ
play
role
induct
chronic
inflammatori
disord
asthma
rheumatoid
arthriti
recent
year
better
pictur
emerg
biolog
regul
illustr
exist
numer
neg
regul
often
play
nonredund
role
target
posit
regul
mani
neg
regul
character
either
involv
direct
interact
prr
dissoci
adaptor
complex
degrad
signal
protein
transcript
regul
posttransl
modif
phosphoryl
ubiquitin
emerg
key
mechan
regul
innat
immun
respons
degrad
signal
protein
mediat
ubiquitinproteasom
autophagi
system
play
crucial
role
neg
regul
tlr
signal
unlik
disrupt
adaptor
regul
innat
immun
novel
target
panvir
therapeut
essaad
et
al
contribut
termin
signal
degrad
irrevers
exampl
includ
protein
soc
promot
polyubiquitin
proteasom
degrad
mal
adaptor
respect
suppress
type
ifn
antivir
respons
recent
mirna
also
emerg
fine
tuner
innat
immun
respons
target
mrna
encod
tlr
intracellular
signal
protein
cytokin
exampl
includ
target
target
ikk
thu
target
specif
neg
regul
innat
immun
respons
may
offer
new
immunotherapeut
strategi
treat
rang
infecti
inflammatori
diseas
cellular
defenc
evolutionarili
challeng
virus
turn
develop
strategi
counteract
innat
immun
respons
inde
tlr
rlr
sens
pathway
fundament
target
virusencod
immun
suppress
viral
subvers
mechan
includ
recruit
ubiquitin
proteasom
system
mimicri
host
cell
compon
sequestr
cleavag
key
compon
immun
system
one
notabl
exampl
mav
adaptor
target
numer
virus
proteolyt
cleavag
hepat
c
viru
hcv
hepat
viru
hav
coxsackieviru
human
rhinoviru
gb
viru
b
gbvb
decreas
mitochondri
membran
potenti
influenza
viru
flu
inhibit
interact
rigi
hepat
b
viru
hbv
process
viral
evas
vari
beyond
scope
review
recapitul
figur
review
importantli
host
protein
target
multipl
virus
highlight
key
player
innat
immun
repres
potenti
therapeut
target
restor
antivir
respons
eventu
cure
cell
virus
howev
specif
viral
evas
strategi
must
also
taken
account
develop
immunomodulatori
therapeut
provid
greatest
clinic
benefit
type
ifn
rapidli
use
therapeut
agent
hbv
hcv
demonstr
antivir
activ
infect
sarscov
flu
west
nile
viru
wnv
yellow
fever
viru
yfv
ebola
viru
refin
therapi
explor
develop
improv
ifn
molecul
like
consensu
interferon
cifn
complet
synthet
interferon
albinterferon
fusion
protein
human
albumin
shape
interferon
recent
virusinduc
type
iii
ifn
gain
lot
interest
treat
viral
infect
sinc
natur
occur
variant
gene
major
predict
factor
spontan
treatmentinduc
clearanc
hcv
earli
clinic
trial
recombin
hcvinfect
patient
show
reduc
advers
effect
compar
ifna
like
link
minim
express
ifnl
receptor
hematopoiet
cell
tlr
target
therapi
tabl
discoveri
tlr
herald
rebirth
interest
innat
immun
specif
recogn
class
pathogen
well
role
pathogenesi
multipl
diseas
repres
strongest
evid
tlr
valuabl
therapeut
target
tlr
target
drug
approv
smallmolecul
compound
investig
treatment
viral
infect
standalon
treatment
adjunct
direct
act
antivir
daa
advanc
exampl
tlr
agonist
imiquimod
aldara
resiquimod
member
imidazoquinolinamin
imiquimod
approv
agonist
use
topic
treatment
extern
genit
perian
wart
result
human
papillomaviru
hpv
infect
resiquimod
mix
agonist
reach
phase
iii
trial
treatment
genit
herp
suspend
due
lack
efficaci
isatoribin
anadi
pharmaceut
second
gener
oral
bioavail
prodrug
isatoribin
signal
express
b
cell
dc
hcv
infect
patient
gener
well
toler
result
signific
log
decreas
hcv
rna
level
follow
day
treatment
assess
phase
iia
efficaci
evalu
combin
ribavirin
daa
ifn
replac
synthet
cytosinephosphateguanin
contain
oligodeoxynucleotid
cpgodn
potent
agonist
interact
directli
dc
stimul
cytokin
releas
induc
adapt
immun
respons
phase
clinic
trial
subcutan
administr
idera
pharmaceut
monotherapi
result
log
decreas
hcv
rna
level
prior
nonrespond
pegifnribavirin
week
combin
ribavirin
log
decreas
hcv
rna
patient
day
basi
efficaci
could
provid
altern
ifn
hcv
therapi
howev
idera
pharmaceut
delay
phase
ii
studi
observ
atyp
lymphocyt
prolifer
preclin
toxicolog
studi
vaccin
adjuv
use
tlr
agonist
tlr
agonist
extens
explor
area
develop
vaccin
adjuv
prophylact
therapeut
applic
link
innat
adapt
immun
system
proofofconcept
approach
made
adjuv
system
combin
monophosphoryl
lipid
mpla
agonist
receptor
aluminium
salt
approv
prophylact
vaccin
hbv
fendrix
glaxosmithklin
hpv
cervarix
glaxosmithklin
mechan
action
mediat
transient
local
activ
nfkb
activ
cytokin
product
thu
provid
innat
immun
signal
optim
activ
apc
notabl
exampl
adjuv
clinic
develop
heplisav
vaxinn
heplisav
hbv
vaccin
compris
immunostimulatori
sequenc
dynavax
technolog
target
receptor
hbv
surfac
antigen
phase
iii
clinic
trial
heplisav
demonstr
earlier
higher
protect
fewer
dose
current
licens
vaccin
vaxinn
corpor
develop
vaccin
use
highli
conserv
influenza
immunogen
fuse
agonist
salmonella
typhimurium
flagellin
type
adjuv
potenti
protect
strain
season
pandem
flu
strain
futur
immunomodulatori
target
therapi
panvir
approach
tabl
past
decad
mani
newli
emerg
reemerg
viru
infect
fear
futur
pandem
accentu
need
novel
antivir
therapi
panvir
therapeut
target
therapi
approach
would
ideal
treatment
acut
chronic
viral
infect
either
standalon
treatment
combin
daa
major
challeng
develop
futur
immunomodulatori
therapi
minim
advers
effect
aggrav
psoriat
plaqu
hpvinfect
patient
treat
imiquimod
illustr
trigger
innat
immun
respons
lead
uncontrol
activ
inflammatori
respons
furthermor
immunomodulatori
molecul
peptidoglycan
bind
multipl
prr
nod
protein
peptidoglycan
recognit
protein
increas
risk
undesir
side
effect
develop
therapeut
requir
extens
structur
inform
receptorligand
interact
maxim
specif
avoid
undesir
interact
select
specif
target
requir
comprehens
knowledg
innat
immun
signal
pathway
regul
induc
common
numer
viral
infect
map
innat
regul
innat
immun
novel
target
panvir
therapeut
essaad
et
al
tabl
develop
statu
tlrtarget
molecul
treatment
viral
infect
immun
protein
interact
network
regul
reveal
signal
modul
high
interconnect
includ
mav
irak
modul
interact
mani
signal
protein
pathway
offer
multipl
drug
target
specif
immun
effector
function
use
genomewid
rnai
screen
assess
virusinduc
transcript
human
cell
identifi
novel
protein
pathway
capabl
neg
posit
regul
innat
immun
respons
unpublish
data
comprehens
epistasi
analysi
variou
regul
act
differ
step
antivir
respons
viru
sens
signal
propagationamplif
feedback
regul
offer
valuabl
inform
select
drug
target
principl
strategi
target
therapi
could
includ
small
moleculemedi
activ
posit
regul
inhibit
neg
regul
exampl
target
neg
regul
could
immunomirna
induc
viru
infect
downregul
ikk
gene
express
suppress
tlr
signal
silenc
function
use
antagomir
lock
nucleic
acid
lna
infect
cell
could
potenti
restor
tlr
signal
better
knowledg
surrog
end
point
measur
maker
immun
effector
function
correl
pan
antivir
efficaci
relev
infect
biolog
materi
undoubtedli
enhanc
select
process
therapeut
valu
drug
target
inde
microarray
analysi
infect
primari
cell
use
identifi
earli
late
respons
innat
immun
gene
well
virusmedi
inhibit
gene
final
knowledg
virusinduc
immun
host
dysfunct
immun
protein
target
multipl
virus
valid
key
viral
host
interfac
lead
hypothesisdriven
select
therapeut
target
intend
restor
innat
immun
respons
tlr
agonist
reflect
substanti
promis
therapeut
target
demonstr
huge
potenti
target
innat
immun
fight
viral
infect
futur
integr
structur
proteom
function
genom
data
pave
way
identif
key
regul
innat
immun
target
immun
regul
promot
prr
signal
maintain
transient
activ
innat
immun
respons
upon
viral
infect
pioneer
discoveri
panvir
therapeut
target
immunomodulatori
therapi
approach
could
chang
way
treat
infecti
diseas
allow
singl
treatment
effect
numer
virus
minim
viral
breakthrough
near
futur
increas
avail
potenc
new
target
immunomodulatori
panvir
therapeut
could
allow
rethink
tempor
aspect
treatment
combin
avail
daa
could
achiev
viral
erad
ultim
goal
shape
tlrdepend
rlrdepend
innat
immun
respons
restor
antivir
effect
gener
optim
global
immun
respons
control
inflamm
tabl
current
futur
develop
immunomodulatori
target
therapi
activ
lead
proinflammatori
cytokin
type
ifn
product
set
pace
adapt
immun
respons
via
b
cell
activ
lead
proinflammatori
cytokin
type
ifn
product
modul
adapt
immun
dc
nk
cell
extens
structur
function
studi
avail
tlr
agonist
market
phase
iiii
clinic
trial
structur
recent
identifi
ssrna
rigi
ligand
reduc
infect
flu
rigi
agonist
adjuv
flu
vaccin
restor
immun
counteract
viral
evas
process
